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Abstract Objective: To determine whether pharmaco-
genetic tests such as N-acetyltransferase 2 (NAT2) and
cytochrome P450 2E1 (CYP2E1) genotyping are useful in
identifying patients prone to antituberculosis drug-induced
hepatotoxicity in a cosmopolite population. Methods: In
a prospective study we genotyped 89 patients treated with
isoniazid (INH) for latent tuberculosis. INH-induced
hepatitis (INH-H) or elevated liver enzymes including
hepatitis (INH-ELE) was diagnosed based on the clinical
diagnostic scale (CDS) designed for routine clinical
practice. NAT2 genotypes were assessed by fluorescence
resonance energy transfer probe after PCR analysis, and
CYP2E1 genotypes were determined by PCR with
restriction fragment length polymorphism analysis.
Results: Twenty-six patients (29%) had INH-ELE,
while eight (9%) presented with INH-H leading to INH
treatment interruption. We report no significant influence
of NAT2 polymorphism, but we did find a significant
association between the CYP2E1 *1A/*1A genotype and
INH-ELE (OR: 3.4; 95% CI:1.1-12; p=0.02) and a
non significant trend for INH-H (OR: 5.9; 95% CI: 0.69–
270; p=0.13) compared with other CYP2E1 genotypes.
This test for predicting INH-ELE had a positive predictive
value (PPV) of 39% (95% CI: 26–54%) and a negative
predictive value (NPV) of 84% (95% CI: 69–94%).
Conclusion: The genotyping of CYP2E1 polymorphisms
may be a useful predictive tool in the common setting of a
highly heterogeneous population for predicting isoniazid-
induced hepatic toxicity. Larger prospective randomized
trials are needed to confirm these results.
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Introduction
Mycobacterium tuberculosis was responsible for two
million deaths and eight million newly infected patients
in 1999 [1]. As its incidence increases world-wide, a
greater number of patients may be at risk for severe adverse
drug reactions (ADRs) when treated with antituberculosis
chemotherapy. Clinically important ADRs induced by
antituberculous agents include liver toxicity [2], neurotox-
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icity (polyneuropathy, optical neuritis, seizure) [3, 4], and
skin (cutaneous eruption), arthritic and gastrointestinal
toxicity [5, 6] with an overall incidence of approximately
5%. The occurrence of ADRs related to INH, particularly
hepatotoxicity, has been well-defined [5] and shown to
increase as a result of drug-drug pharmacokinetic or
pharmacodynamic interactions [7–11].
INH is mainly inactivated by N-acetyltransferase 2
(NAT2)-mediated acetylation, resulting in acetylisoniazid
(Fig 1), which is hydrolyzed to acetylhydrazine. The latter
is further oxidized by cytochrome P4502E1 (CYP2E1) to
form hydroxylamines, which are intermediates in the
formation of established hepatotoxic metabolites [12–15].
There are large variations in the metabolism of the
antituberculous drug isoniazid, suggesting a pharmacoge-
netic polymorphism of NAT. This enzyme is markedly
decreased in livers of slow acetylators (SA). The official
nomenclature of the NAT2 polymorphism can be found
on the official website: http://louisville.edu/medschool/
pharmacology/NAT2.html. The elimination of INH has
been described to follow a bimodal and even a trimodal
distribution consisting of slow (SA), intermediate (IA) and
rapid actetylators (RA), and there is a strong correlation
(from 0.93 to 1 in the Caucasian population) between these
phenotypes and NAT2 genotypes [13, 16–18]. The main
clinical interest in the NAT2 polymorphism is the presumed
association of the phenotype with the therapeutic response
and the occurrence of ADRs. The SA polymorphism has
been suspected to be a risk factor for INH-induced
hepatotoxicity but despite numerous studies, the contro-
versy still remains [13, 14, 16–21].
On the other hand, CYP2E1 is a major ethanol-induced
microsomal enzyme expressed in the liver and in other
organs such as the kidney, lung, nasal mucosa, brain and
lymphocytes [22]. Because of its wide range of substrates
(aromatic and halogenated hydrocarbons, halogenated
anaesthetics, alcohols, nitrosamines…), this cytochrome
plays an important role in the field of clinical toxicology
[23]. Several CYP2E1 genetic polymorphisms are cur-
rently detectable applying techniques involving the RsaI,
TaqI, DraI and PstI restriction enzymes, but the clinical
significance of these polymorphisms remains unclear,
partly because no convincing association between
CYP2E1 catalytic activities and their genotypes has been
demonstrated [24–26].
In the study reported here, we found that CYP2E1 was
involved in INH metabolism and that its c1/c1 genotype
(RsaI polymorphism) was an independent risk factor for
antituberculous agents-induced hepatitis after adjustment
for NAT2 acetylator status and age in the Asian population
[27, 28].
Patients and methods
The protocol was approved by the local ethics committee
and written informed consent was obtained from all
participants.
Patients
Between October 2001 and March 2003, 103 consecutive
outpatients (53 men and 50 women) with primary tuber-
culosis were asked to participate in this prospective study.
Inclusion criteria consisted of the patients having latent
tuberculosis as defined by the American Thoracic Society
[29] with normal plasma aspartate transaminase (AST) and
alanine transaminase (ALT) levels prior to the beginning of
INH monotherapy. Exclusion criteria consisted of a history
of alcohol consumption, positive serology for the
hepatitis A virus (HAV), hepatitis B virus (HBV) or
hepatitis C virus (HCV), poor chemotherapy compliance
(negative urine INH three times during the follow-up), loss
during the follow-up or if the patients had to receive
supplementary antituberculosis agents or other potentially
hepatotoxic drugs.
Of the initial sample of 103 patients, three (two women,
one man) were excluded because of active B hepatitis
(positive HBs antigen). During follow-up, 11 additional
patients (seven women, four men) had to be excluded: five
patients because they had to receive supplementary
antituberculosis chemotherapy, four were lost during the
follow-up and two were excluded because of poor
compliance. At the end of the study period, 89 patients
were evaluated. Among these, 40 (45%) were women,
Median age was 31 years (range: 17–73 years), with a
value between the first and the third quartile ranging
from 24 to 41 years of age. Thirty eight patients (43%)
were Caucasians, eight (9%) were Hispanic, 22 (25%)
were African, 15 (17%) were South Americans, five
(6%) were Asians and one (1%) was native to the Middle
East.
Before treatment, each patient was emphatically re-
quested to refrain from any alcohol consumption and self-
medication without first reporting it. Five patients (6%)
were taking various medications before being enrolled in
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Fig. 1 Pathways of isoniazid metabolism. Scheme illustrating the
metabolism of isoniazid through multiple pathways. The main
(confirmed) pathways are indicated by continuous arrows, while a
hypothetical alternative pathway is shown with a dotted arrow. The
two enzymes involved in these pathways and genotyped in the
present study are located within boxes
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the study: one was treated with omeprazole 40 mg for a
gastritis, one with ciprofloxacine for 5 days because of an
urinary tract infection, one took losartan and simvastatine
because of hypertension and dyslipidemia, one was treated
with metformin, omeprazole and venlafaxine because of
diabetes, gastroesophageal reflux disease and depression
and one patient was treated with glibenclamide, metformin,
nifedipin, furosemid, enalapril and aspirin because of
diabetes and hypertension. All of the patients participating
in the study were treated with isoniazid (INH) 300 mg daily
and vitamin B6 40 mg per day for a period of 6 months.
Liver function, chemotherapy compliance (positive urine
INH test), response to rechallenge (when performed) and
risk factors such as alcohol use, pregnancy or concomitant
use of drugs were assessed twice a month by an indepen-
dent investigator.
Criteria for the diagnosis of INH-induced hepatitis
(INH-H) consisted of elevation in AST and/or ALT levels
fourfold above the upper reference limit (168 UI/l) with or
without symptoms. These criteria are routinely used by our
institution pneumologists and gastroenterologists and are
in accordance with the recommendations of Ozick et al.
[31] and consistent with the recommendations of the
American Thoracic Society (ATS) [43]. In the case of INH-
induced hepatitis, INH was withdrawn and replaced by
rifampicin. INH-induced elevated liver enzymes (INH-
ELE) was defined as serum ALT and/or AST values above
URL (42 UI/l) with or without INH-H. Clinical Diagnostic
Scales (CDS) were used to assess the likelihood of drug
involvement when INH-H or INH-ELE were suspected
[32]. Based on the CDS, causality assessment of INH-H
and INH-ELE was then categorized as definite (score >17),
probable (14–17), possible (10–13), unlikely (6–9) or
excluded (<6). INH-H and INH-ELE with possible to
probable scores (≥10–17) were considered for statistical
analysis; unlikely scores were still considered when no
other factor (see above) was identifiable.
Methods
DNA extraction
Genomic DNA was extracted from 200 μl of heparinized
frozen whole blood using the the Qiagen (Germantown,
Md) DNA Blood Minikit and following the manufacturer’s
instructions.
NAT2 genotype
Four major NAT2 polymorphic forms were investigated in
the individual samples by real time PCR on LightCycler
using fluorescence resonance energy transfer (FRET) with
hybridization of allele-specific probes for detection.
Briefly, simultaneous analysis of NAT2*5A (C→T at
position 481), NAT2*6A (G→A at position 590),
NAT2*7A/B (G→A substitution at position 857) and
NAT2*14A (G→A substitution at position 191) alleles was
achieved by performing a dual color recording as indicated
by the manufacturer of the kit (Roche, Basel, Switzerland).
At the end of the amplification cycle, unambiguous
determination of the different genotypes was achieved by
melting curve analysis.
CYP2E1 genotype
For CYP2E1 genotyping, PCR was performed in the
GeneAmp 9600 Thermocycler (PerkinElmer, Foster City,
Calif.) with an activation step (10 min, 95°C), a two-
temperature thermal cycling profile, (35 cycles of 20 min at
94°C and 1 min at 62°C) and a final elongation step (7 min
at 72°C). The PCR mixture contained: Taq Gold Dna
polymerase (2.5 U/rxn), 25 mM MgCl (1.75 mM), 10×
PCR Gold buffer (1×), 10 mM dNTP blend (200 μM each),
10 μM forward and reverse primers (0.5 μM) in a 50 μl rxn
volume. The template was approximately 100 ng of
genomic DNA . All reagents were purchased from Applied
Biosystems (Foster City, Calif.).
The four primer sequences wereRsa forward (CCAGTC
GAGTCTACATTGTCA) and reverse (TTCATTCTGTCTTC
TAACTGG), and Taq forward (GGGCTTTCATCTTCATTTC
GA) and reverse (CAAAATGTGGGCTTTCATCTG).
RsaI and TaqI restriction enzymes were purchased from
Biogen (Cambridge, Mass.). Restriction mixtures were
prepared with specific buffers (provided) and 1 U/rxn of
enzyme. Twenty-microliter aliquots of PCR product were
digested either at 37°C for 3 h with the RsaI mixture or at
65°C for 3 h with the the TaqI mixture.
Electrophoretic separation and fragment analysis were
achieved on a 2% agarose gel. Restriction fragments were
of the expected size: the RsaI+ (C1) wild allele produced
two fragments of 351 and 61 bp, respectively, while the
RsaI− (C2) mutant allele yielded one single fragment of
413 bp. For TaqI analysis, the TaqI+ (A2) wild type allele
was identified from its two fragments, of 80 and 74 bp;
while the TaqI− (A1) mutant allele produced one single
fragment of 154 bp. The heterozygous mutant showed all
the three fragments on the gel. According to the
recommended nomenclature of CYP 2E1 (http://www.
imm.ki.se/CYPalleles), genotypes were determined by the
combination of these RFLP:
– *1A (wild-type allele) = RsaI+, TaqI+ (C1, A2);
– *1B = TaqI− (independently of RsaI) (A1);
– *5 = RsaI− (independently of TaqI) (C2).
Because analyses of the PstI and DraI polymorphisms
were not performed, further characterization of the *5
genotype in *5A or *5B were carried out.
Serology and clinical chemistry
Serum liver tests were determined using a LX-20 analyzer
(Beckmann-Coulter, Brea, Calif.), and serology for viral
hepatitis was assessed using commercially available
immunoassays (Abott Laboratories, Chicago, Ill.).
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Statistics
Data were expressed as median with first (Q1) and third
(Q3) quartiles. Proportions, odds ratios (OR) and 95%
exact confidence intervals (95% CI) were calculated
using> STATXACT-3 software. Chi-square test, Fisher’s
exact test and trend tests were used to compare groups of
patients. A two-sided p value was considered to be
significant when below 0.05. Clinical sensitivities (SN)
and specificities (SP) and negative (NPV) and positive
predictive values (PPV) were assessed for association with
INH-induced hepatitis (INH-H) and INH-induced elevated
liver enzymes (INH-ELE), with or without hepatitis,
against different CYP2E1 and NAT2 genotypes.
Results
Of the 89 patients, 26 (29%) had elevated liver enzymes
(Table 1). Six of the 8 patients with hepatitis that led to
treatment interruption were symptomatic. The ALT values
ranged from 177 to 2005 IU/l for INH-H. It is noteworthy
that none of the five patients taking other concomitant
medications presented with INH-H or INH-ELE.
Overall the analysis of the likelihood of INH involve-
ment in elevated enzymes (CDS score) led to six patients
(23%) being classified as having a probable association
with INH and 14 (54%) as having a possible association
with INH, whereas six patients (23%) were considered
unlikely to be related. None were of these classifications
are definite (data not shown).
There was a clear, although non-significant, trend
showing that increasing age was associated with a higher
incidence of INH-ELE and INH-H, but there was no gender
difference (Table 1).
Of the 89 patients, nine (10%) were genotyped as RA, 45
(51%) as IA and 35 (39%) as SA. The genotype
frequencies reported here were not markedly different
from those predicted by the Hardy-Weinberg equation
(Table 2) [33]. The risk of having INH-H or INH-ELE was
independent of NAT2 acetylator status (Tables 3, 4). In
contrast, the risk of having INH-ELE was significantly
associated to the CYP2E1 *1A/*1A genotype. and for this
genotype, the risk having an INH-ELE was 3.4-fold higher
(OR: 3.4; 95% CI:1.1–12; p=0.02) when compared with all
other CYP2E1 genotypes (Tables 3, 4). Although non-
significant, a trend was also identified showing that the
CYP2E1 *1A/*1A genotype was associated with a higher
incidence of INH-H in comparison to other CYP2E1
genotypes (OR:5.9; 95%CI:0.69–270; p= 0.13).
Among patients that developed an INH-ELE with a
CYP2E1*1A/*1A genotype, the distribution of NAT2
genotype was identical to that observed in the general
population (data not shown).
When tested for predicting INH-ELE, the CYP2E1 *1A/
*1A genotype yielded a specificity of 51% (95% CI: 35–
57%) and a sensitivity of 77% (95% CI: 56–91%) with a
PPV of 39% (95% CI: 26–54%) and a NPV of 84% (95%
CI:69–94%). For the INH-H group, the SP was 46% (95%
CI: 35–57%), the SN reached 87% (95% CI: 47–100%),
the PPV was 14% (95% CI: 6–26%) and the NPV was 84%
(95% CI: 69–94%), (Table 5).
In order to test a potential allele-allele interaction
between NAT2 and CYP2E1 polymorphisms, we per-
Table 2 Distributiona of NAT2 and CYP2E1 genotypes
Genotype Observed
N
Frequency
(%)
95% CI
(%)
Expected
Frequency by
Hardy-
Weinberg (%)
NAT2
Rapid acetylators 9 10 –
NAT2*4/*4 9 10 4.7–18 12.5
Intermediate
acetylators
45 51 –
NAT2*4/*5 20 22 14–33 19.9
NAT2*4/*6 22 25 16–35 23.0
NAT2*4/*7 2 2 0.27–7.9 2.4
NAT2*4/*14 1 1 0.03–6.1 0.3
Slow
acetylators
35 39 –
NAT2*5/*5 8 9 4.0–17 7.9
NAT2*5/*6 11 12 6.3–21 18.3
NAT2*5/*7 3 3 0.70–9.5 1.9
NAT2*6/*6 12 13 7.2–22 10.6
NAT2*6/*7 1 1 0.03–6.1 2.2
CYP2E1
*1A/*1A 51 57 46–68 55.8
*1A/*1B 26 29 20–40 31.8
*1A/*1B 5 6 2–13 4.5
*1A/*5 5 6 2–13 5.9
*1B/*5 2 2 0.3–8 1.7
*5/*5 0 0 0–4 0.2
aAll patients were genotyped for NAT2 (alleles *4, *5, *6, *7, *14)
and CYP2E1 (alleles *1A, *1B and *5) enzymes. The observed
frequencies were compared to those expected from Hardy-
Weinberg analysis
Table 1 Incidencea of isoniazid-induced hepatitis (INH-H) and
isoniazid-induced elevated liver enzymes (INH-ELE) as a function
of sex and age
Category n INH-H INH-ELE
Global 89 8 (9%) 26 (C29%)
Sex
Females 40 5 (13%) 9 (22%)
Males 49 3 (6%) 17 (35%)
p value (Fisher) 0.46 0.25
Age
≤26 29 1 (3%) 6 (21%)
27–35 30 2 (7%) 8 (27%)
≥36 30 5 (17%) 12 (40%)
p value (Trend test) 0.10 0.10
aNon-parametric tests performed on these results did not reveal any
significant difference among groups
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formed separate analyses combining the CYP2E1 wild-
type and mutant alleles with the NAT2 wild-type and
mutant alleles in patients with INH-H and INH-ELE. No
significant result was observed.
Discussion
On the basis of our study we are able to report a significant
association between the CYP2E1 *1A/*1A genotype and
the risk of developing INH-induced hepatotoxicity without
hepatitis, with a sensitivity for the CYP2E1 mutant
genotype of 77% (95% CI: 56–91%) and a negative
predictive value of 84% (95% CI: 69–94%), suggesting a
possible protective role of any of the CYP2E1 mutants.
These results are consistent with those of Wong et al. who
suggested that the A1 allele (*1B, according to the new
nomenclature) in the homo- or heterozygous form had a
possible protective role in alcoholic liver disease [25] and
with those of Huang showing that CYP2E1 RsaI polymor-
phism was associated with susceptibility to INH-induced
hepatotoxicity [27]. Although the role of CYP2E1 might be
different for alcoholic liver disease and INH-induced
hepatotoxicity, [27] these results are in agreement the
current hypothesis depicted in Fig. 1 and emphasise the
critical role of CYP2E1 in generating potential hepatotoxic
compounds [12–15]. Although our population was small
and highly heterogeneous, the possibility that this statis-
tical association might stem from a population stratification
can be excluded as we performed our statistical analyses
always considering the 89 patients as a unique group,
irregardless of their ethnic origin. Although nonsignificant,
we also reported a trend between the wild-type CYP2E1
genotype and the likelihood to develop INH-H. The most
likely explanation for this lack of statistical signification is
a type II error because of the small number of patients
enrolled in this study. The other striking finding of our
study is that our results failed to show any significant
association between NAT2 susceptibility to INH-induced
hepatotoxicity in contrast to the recent studies performed
with Asian populations [19, 28]. Several explanations of
this apparently contradictory observation can be proposed.
First, these discrepancies might well result from a
different genotype distribution among Asian and European
patients. The NAT2 genotypes and phenotypic (based upon
genotype) [13, 16–18] distributions obtained in this study
included fewer SA phenotypes than expected. Only 10%
RA phenotypes were found, whereas 50% are expected in a
Caucasian population [13, 16, 18]. Even if NAT2 allelic
distributions were consistent with those predicted by the
Hardy-Weinberg equation, they were markedly different
from those obtained in Asian populations [27, 28, 34].
Hence, it is likely that the heterogeneity of our population
accounts for these differences as important genotype/
phenotype prevalences of SA variations occur in accor-
dance to the ethnic group considered (Oriental, 10%;
Caucasian, 50%; Egyptian, 80%) [13, 16, 35, 36]. Another
explanation could be related to the difference in the
treatments between our study and the three Asian ones [19,
27, 28]. Indeed, in our study, patients were treated with
300 mg of INH daily, whereas 600 mg INH was prescribed
in the other studies. More importantly, patients in the Asian
studies were treated with two to four antituberculosis
agents (rifampicin, ethambutol, pyrazinamid and INH) [19,
27, 28]. As rifampicin is known to reduce NAT2 activity
[38, 39], as INH is known to have a biphasic effect on
CYP2E1 activity (initial inhibition followed by an induc-
tion) [40] and because a combination of these drugs is
known to increase the incidence of antituberculous drug-
induced hepatotoxicity up to 35% [37–41], drug-drug
pharmacokinetic and pharmacodynamic interactions cer-
Table 4 Relative riska of isoniazid-induced liver dysfunction
among various genotypes
Genotype INH-H events INH-ELE events
OR 95% CI OR 95% CI
NAT-2
RA 1.00 – 1.00 –
IA 0.78 0.065–43 1.00 0.18–7.0
SA 0.75 0.052–44 0.59 0.10–4.5
CYP2E1
*1A/*1A 5.9 0.69–270 3.4 1.1–12
Others 1.00 – 1.00 –
aThe odds ratio (OR) and their 95% confidence interval (CI) for
susceptibility of each genotype group to INH-H and INH-ELE is
indicated in the table
Table 3 Susceptibility of INH-H and INH-ELE in each genotype
group
Genotypes n With adverse events
INH-H (%) INH-ELE (%)
NAT2
Rapid Acetylators (RA) 9 1 (11) 3 (33)
NAT2*4/*4 9 1 (11) 3 (33)
Intermediate Acetylators (IA) 45 4 (9) 15 (33)
NAT2*4/*5 20 2 (10) 6 (30)
NAT2*4/*6 22 2 (9) 8 (36)
NAT2*4/*7 2 0 (0) 1 (50)
NAT2*4/*14 1 0 (0) 0 (0)
Slow Acetylators (SA) 35 3 (9) 8 (23)
NAT2*5/*5 8 1 (13) 2 (25)
NAT2*5/*6 11 0 (0) 2 (18)
NAT2*5/*7 3 1 (33) 1 (33)
NAT2*6/*6 12 1 (8) 3 (25)
NAT2*6/*7 1 0 (0) 0 (0)
p value (RA vs. IA vs. SA)
CYP2E1
*1A/*1A 51 7 (14) 20 (39)
*1A/*1B 26 0 (0) 4 (15)
*1B/*1B 5 0 (0) 0 (0)
*1A/*5 52 1 (20) 1 (20)
*1B/*5 0 (0) 1 (50)
p value (*1A/*1A vs. others) 0.13 0.02
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tainly did occur. As such, these pharmacodynamic and
pharmacokinetic interactions are very likely to represent a
major confounding factor impeding proper interpretation of
the results obtained in these studies. The patients in the
present study were under monotherapy (INH alone) and
because none of the five patients receiving other concom-
itant medications presented INH-hepatitis or INH-elevated
liver enzyme, these potential interactions did not occur in
our study. A third possible explanation is that in the presence
of a highly heterogeneous population, NAT2 genotyping its
predictive value. CYP2E1 genotyping could therefore
represent the most appropriate test to perform in an
ethnically heterogeneous population. Other caveats could
be related to methodological issues of our study, such as a
type II error because our population was smaller than those
evaluated by Huang et al. [27, 28] and Ohno et al. [19].
Finally, the incidence of INH-induced enzyme activity
(INH-ELE and INH-H) reported here (26/89; 29%) was
higher than any value previously reported (1–5%) and
might be related to the fact that most of the earlier studies
did not consider the elevation in liver enzymes in their
analysis [5, 30, 31, 41]. The incidence of INH-induced
hepatitis reported here was also higher (9% versus 1–5%)
than reported in the literature [5, 30, 31, 41]. As suggested
by Huang et al., the real incidence of INH-induced adverse
events, in particular INH-induced hepatitis, could well
have been underestimated in previous studies in the
absence of systematic assessment [27, 28]. For example,
the United States Public Health Service study showed a
INH-induced hepatitis incidence of 1% [30], but liver
function was controlled only when clinical signs were
present and not in a systematic manner as was done in the
present study. Furthermore, recent reports show that the
prevalence of INH-induced hepatotoxicity is consistently
higher than previously thought, with a frequency reaching
13–26% and even 35% in one Japanese study [27, 30, 41–
43]. In this perspective, our results support the hypothesis
that the frequency of INH-induced hepatotoxicity might
have been underestimated.
In conclusion, this study shows for the first time that the
CYP2E1 *1A/*1A polymorphism may confer a greater risk
of INH-induced hepatotoxicity in the setting of a hetero-
geneous ethnic population. Because of the acceptable NPV
of any CYP2E1 mutant allele obtained in the present study,
this test could be of clinical utility in the setting of a
cosmopolite population. Because ethnic heterogeneity
represents the daily reality most clinicians have to deal
with, we thought it important to test the potential predictive
value of genotyping in this common setting. However, due
to the small number of patients enrolled in this study, these
results must be considered as preliminary and need to be
replicated in a larger sample. Nevertheless, our results do
suggest that the CYP2E1 genotype could be a much more
robust and independent predictive parameter when evalu-
ating the risk of experiencing hepatic adverse effects with
antituberculosis drugs than the NAT2 genotype when
applied to an ethnically heterogeneous population.
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